CN107108534B - 用于成像亨廷顿蛋白的探针 - Google Patents

用于成像亨廷顿蛋白的探针 Download PDF

Info

Publication number
CN107108534B
CN107108534B CN201580058282.3A CN201580058282A CN107108534B CN 107108534 B CN107108534 B CN 107108534B CN 201580058282 A CN201580058282 A CN 201580058282A CN 107108534 B CN107108534 B CN 107108534B
Authority
CN
China
Prior art keywords
pyridin
methoxy
mmol
methyl
benzoxazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580058282.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN107108534A (zh
Inventor
C·多敏古兹
J·维恰克
J·巴德
A·基谢廖夫
C·J·布朗
S·R·G·加兰
M·E·普莱姆
P·R·贾尔斯
E·L·P·加杜洛
T·M·克吕尔
D·克拉克-弗鲁
P·D·约翰逊
S·科伊
S·海耶斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHDI Foundation Inc
Original Assignee
CHDI Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHDI Foundation Inc filed Critical CHDI Foundation Inc
Priority to CN202310475134.8A priority Critical patent/CN116655618B/zh
Publication of CN107108534A publication Critical patent/CN107108534A/zh
Application granted granted Critical
Publication of CN107108534B publication Critical patent/CN107108534B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room
    • A61B5/0035—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for acquisition of images from more than one imaging mode, e.g. combining MRI and optical tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/032—Transmission computed tomography [CT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Pulmonology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201580058282.3A 2014-08-29 2015-08-28 用于成像亨廷顿蛋白的探针 Active CN107108534B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310475134.8A CN116655618B (zh) 2014-08-29 2015-08-28 用于成像亨廷顿蛋白的探针

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462043603P 2014-08-29 2014-08-29
US62/043,603 2014-08-29
PCT/US2015/047407 WO2016033445A1 (en) 2014-08-29 2015-08-28 Probes for imaging huntingtin protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310475134.8A Division CN116655618B (zh) 2014-08-29 2015-08-28 用于成像亨廷顿蛋白的探针

Publications (2)

Publication Number Publication Date
CN107108534A CN107108534A (zh) 2017-08-29
CN107108534B true CN107108534B (zh) 2023-05-09

Family

ID=55400648

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310475134.8A Active CN116655618B (zh) 2014-08-29 2015-08-28 用于成像亨廷顿蛋白的探针
CN201580058282.3A Active CN107108534B (zh) 2014-08-29 2015-08-28 用于成像亨廷顿蛋白的探针

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202310475134.8A Active CN116655618B (zh) 2014-08-29 2015-08-28 用于成像亨廷顿蛋白的探针

Country Status (20)

Country Link
US (3) US10479802B2 (enExample)
EP (2) EP3186233B8 (enExample)
JP (2) JP6817207B2 (enExample)
KR (2) KR102456946B1 (enExample)
CN (2) CN116655618B (enExample)
AU (1) AU2015308774B2 (enExample)
BR (1) BR112017004141B8 (enExample)
CA (1) CA2959501C (enExample)
DK (1) DK3186233T3 (enExample)
EA (1) EA035646B1 (enExample)
ES (1) ES2898965T3 (enExample)
HR (1) HRP20211778T1 (enExample)
HU (1) HUE056957T2 (enExample)
IL (1) IL250803B (enExample)
MX (2) MX380810B (enExample)
PL (1) PL3186233T3 (enExample)
PT (1) PT3186233T (enExample)
SG (1) SG11201701600QA (enExample)
SI (1) SI3186233T1 (enExample)
WO (1) WO2016033445A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107074817B (zh) 2014-08-29 2023-12-15 Chdi基金会股份有限公司 用于成像亨廷顿蛋白的探针
DK3197277T3 (da) 2014-08-29 2022-01-31 Chdi Foundation Inc Prober til billeddannelse af huntingtin-protein
KR102456946B1 (ko) 2014-08-29 2022-10-21 씨에이치디아이 파운데이션, 인코포레이티드 헌팅틴을 단백질 영상화하기 위한 프로브
SG11201701580XA (en) 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein
MX382156B (es) 2015-08-28 2025-03-13 Chdi Foundation Inc Sondas para formar imagenes de proteina de huntingtina.
BR112018068066B1 (pt) 2016-03-11 2023-11-28 Ac Immune Sa Compostos bicíclicos e seu uso, composição diagnóstica e farmacêutica, misturas, métodos de coleção de dados para diagnóstico, para determinar uma predisposição a, para monitorar transtorno residual e para prever a capacidade de resposta de um paciente sofrendo de transtorno ou anormalidade associado com agregados de alfa-sinucleína, métodos para determinar a quantidade de agregados de alfa-sinucleína e para preparar um composto, kit teste e kit para preparar uma preparação radio farmacêutica
CN107056723A (zh) * 2017-04-21 2017-08-18 云南大学 一种具有抑制血管内皮生长因子受体信号传导的化合物
NZ763299A (en) 2017-09-14 2025-09-26 Daiichi Sankyo Co Ltd Compound having cyclic structure
US20210169080A1 (en) 2018-04-20 2021-06-10 Bayer Aktiengesellschaft Heterocycle derivatives as pesticides
JP7397492B2 (ja) 2018-06-08 2023-12-13 エーシー・イミューン・エス・アー 診断のための二環式化合物
EP3897630B1 (en) 2018-12-21 2024-01-10 Celgene Corporation Thienopyridine inhibitors of ripk2
US11389438B2 (en) 2019-02-25 2022-07-19 Chdi Foundation, Inc. Compounds for targeting mutant huntingtin protein and uses thereof
CN111635400A (zh) 2019-03-02 2020-09-08 察略盛医药科技(上海)有限公司 吡唑并[1,5-a]吡啶类衍生物、及其制备方法和用途
ES3029867T3 (en) * 2019-12-18 2025-06-25 Chdi Foundation Inc Compounds and probes for imaging huntingtin protein
MX2022008627A (es) 2020-01-13 2022-11-08 Verge Analytics Inc Pirazolo-pirimidinas sustituidas y usos de las mismas.
EP4146653A1 (en) 2020-05-07 2023-03-15 AC Immune SA Novel compounds for diagnosis
WO2022031946A1 (en) * 2020-08-06 2022-02-10 Chdi Foundation, Inc. Heterobiaryl compounds and imaging agents for imaging huntingtin protein
CA3214756A1 (en) * 2021-04-08 2022-10-13 Longbin Liu Isoindolinone compounds and imaging agents for imaging huntingtin protein
MX2023012652A (es) * 2021-04-27 2024-01-08 Chdi Foundation Inc Compuestos deuterados y agentes de imagen para representar la proteína huntingtina.
WO2023283425A1 (en) 2021-07-09 2023-01-12 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2
WO2023083961A1 (en) 2021-11-10 2023-05-19 Ac Immune Sa Dihydropyrrolo[3,4-c]pyrazole derivatives and their use in diagnosis
CA3235230A1 (en) 2021-11-10 2023-05-19 Jerome Molette 4h-imidazo[1,5-b]pyrazole derivatives for diagnosis
JP2024544521A (ja) 2021-11-10 2024-12-03 エーシー・イミューン・エス・アー ジヒドロピロロ［３，４ｃ］－ピラゾール誘導体及び診断におけるその使用
TW202425965A (zh) 2022-09-30 2024-07-01 日商科研製藥股份有限公司 縮環化合物及含有其之醫藥
WO2024126842A1 (en) 2022-12-16 2024-06-20 Ac Immune Sa Novel compounds for diagnosis
CN120344536A (zh) 2022-12-16 2025-07-18 Ac免疫有限公司 用于诊断的新化合物
AU2024271346A1 (en) * 2023-05-18 2025-11-27 Enveda Therapeutics, Inc. G-protein coupled receptor antagonist
WO2025037013A1 (en) 2023-08-16 2025-02-20 Ac Immune Sa Diagnostic compounds that bind to alpha-synuclein
WO2025106920A1 (en) * 2023-11-15 2025-05-22 Yale University Parp pet imaging agents and methods of using the same
CN119264072B (zh) * 2024-12-06 2025-05-02 国科大杭州高等研究院 对细胞成像的荧光探针及其合成方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080267879A1 (en) * 2007-04-27 2008-10-30 The General Hospital Corporation Novel Imaging Tracers for Early Detection and Treatment of Amyloid Plaques Caused by Alzheimer's Disease and Related Disorders
US20090123373A1 (en) * 2007-11-05 2009-05-14 Yanming Wang Amyloid-imaging agents
WO2010051196A1 (en) * 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel substituted azabenzoxazoles
WO2010112093A1 (en) * 2009-04-02 2010-10-07 Biomarin Iga, Ltd. Benzoxazoles for the treatment of duchenne muscular dystrophy
US20110085985A1 (en) * 2008-05-30 2011-04-14 Barrow James C Novel substituted azabenzoxazoles

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985755A (en) 1972-06-02 1976-10-12 E. R. Squibb & Sons, Inc. Pyridine containing isothiocyanobenzoxazoles
US4198416A (en) 1976-09-30 1980-04-15 Meiji Seika Kaisha, Ltd. 5-Alkoxy-picolinic esters and anti-hypertensive composition containing 5-alkoxy-picolinic esters
DE2909754A1 (de) * 1979-03-13 1980-09-18 Thomae Gmbh Dr K Neue benzofuran- und benzothiophenderivate, deren herstellung und deren verwendung als arzneimittel
FR2524468B1 (fr) 1982-04-06 1985-10-18 Sandoz Sa Nouveaux derives condenses du thiophene, leur preparation et leur utilisation comme azurants optiques
JP2869561B2 (ja) * 1989-05-22 1999-03-10 大塚製薬株式会社 血小板粘着抑制剤
US5041453A (en) 1990-05-30 1991-08-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Quinolinyl-benzoheterobicyclic derivatives as antagonists of leukotriene D4
JP2600644B2 (ja) 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
GB9203798D0 (en) 1992-02-21 1992-04-08 Fujisawa Pharmaceutical Co Quinolylbenzofuran derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
WO1994022846A1 (en) * 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
GB9317949D0 (en) * 1993-08-28 1993-10-13 Stevens Malcolm F G Benzothiazole compounds
ES2163587T3 (es) 1995-02-28 2002-02-01 Lilly Co Eli Compuestos de benzotiofeno, productos intermedios, composiciones y procedimientos.
JPH08325265A (ja) * 1995-05-29 1996-12-10 Fujisawa Pharmaceut Co Ltd チアゾリルベンゾフラン誘導体の製造方法、および該製造方法に用いられる化合物
WO1997027190A1 (en) 1996-01-22 1997-07-31 Fujisawa Pharmaceutical Co., Ltd. Thiazolylbenzofuran derivatives and pharmaceutical compositions containing them
JPH11171886A (ja) 1997-12-08 1999-06-29 Mitsui Chem Inc アミジンまたはグアニジンを側鎖にもつピロリルベンズイミダゾール誘導体
US6573264B1 (en) 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
US7163952B2 (en) * 2001-12-03 2007-01-16 Japan Tobacco Inc. Azole compound and medicinal use thereof
PL210413B1 (pl) 2001-12-20 2012-01-31 Wyeth Corp Pochodne indoliloalkiloaminy
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
WO2005040337A2 (en) 2003-05-20 2005-05-06 The Regents Of The University Of California METHODS FOR BINDING AGENTS TO β-AMYLOID PLAQUES
WO2005016384A1 (ja) 2003-08-13 2005-02-24 Bf Research Institute, Inc. アミロイド蓄積性疾患のプローブ、アミロイド染色剤、アミロイド蓄積性疾患の治療および予防薬、ならびに神経原線維変化の診断プローブおよび染色剤
TW200616974A (en) 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
KR20080094699A (ko) 2006-02-15 2008-10-23 사노피-아벤티스 신규 아미노알콜-치환된 아릴디하이드로이소퀴놀리논, 이의제조 방법 및 이의 약물로서의 용도
EP2054060B1 (en) 2006-08-24 2014-04-02 Australian Nuclear Science & Technology Organisation Fluorinated ligands for targeting peripheral benzodiazepine receptors
JP5190893B2 (ja) * 2006-12-25 2013-04-24 国立大学法人東北大学 ベンゾキサゾール誘導体
KR101469275B1 (ko) 2007-06-01 2014-12-08 재단법인서울대학교산학협력재단 베타아밀로이드 침착의 영상화를 위한 헤테로사이클릭 인덴계열의 유도체 및 그의 방사성 동위원소 표지화합물
CA2700841A1 (en) 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
WO2009146388A1 (en) 2008-05-28 2009-12-03 The Trustees Of Columbia University In The City Of New York Voxel-based methods for assessing subjects using positron emission tomography
WO2009155024A1 (en) * 2008-05-30 2009-12-23 Merck & Co., Inc. Novel substituted indoles
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
PL2414369T3 (pl) 2009-04-02 2016-04-29 Fundacion Centro Nac De Investigaciones Oncologicas Carlos Iii Pochodne imidazo[2,1-b][1,3,4]tiadiazolu
ES2620177T3 (es) 2009-10-15 2017-06-27 Guerbet Agentes de formación de imágenes y su uso para el diagnóstico in vivo de enfermedades neurodegenerativas, particularmente la enfermedad de Alzheimer y enfermedades derivadas
JP2011168515A (ja) 2010-02-17 2011-09-01 Kowa Co エリスロポエチン産生促進作用を有する２−アリールベンゾオキサゾール化合物
WO2012007510A1 (en) * 2010-07-14 2012-01-19 Bayer Pharma Aktiengesellschaft Compounds for binding and imaging amyloid plaques and their use
PH12013501099A1 (en) 2010-11-30 2013-07-08 Takeda Pharmaceuticals Co Bicyclic compound
CN102391260B (zh) 2011-09-29 2014-12-10 上海交通大学 3-甲酮-6-取代-苯并呋喃类化合物及其制备方法和用途
CN104540835B (zh) 2012-04-26 2017-08-08 百时美施贵宝公司 用于治疗血小板聚集的作为蛋白酶激活受体4(par4)抑制剂的咪唑并噻二唑衍生物
US9370588B2 (en) 2013-01-04 2016-06-21 University Of Massachusetts Luciferin amides
GB201306248D0 (en) * 2013-04-05 2013-05-22 Ucl Business Plc Compounds and their uses
JP6503336B2 (ja) 2013-07-17 2019-04-17 大塚製薬株式会社 シアノトリアゾール化合物
DK3197277T3 (da) 2014-08-29 2022-01-31 Chdi Foundation Inc Prober til billeddannelse af huntingtin-protein
SG11201701580XA (en) 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein
CN107074817B (zh) 2014-08-29 2023-12-15 Chdi基金会股份有限公司 用于成像亨廷顿蛋白的探针
KR102456946B1 (ko) 2014-08-29 2022-10-21 씨에이치디아이 파운데이션, 인코포레이티드 헌팅틴을 단백질 영상화하기 위한 프로브
MX382156B (es) 2015-08-28 2025-03-13 Chdi Foundation Inc Sondas para formar imagenes de proteina de huntingtina.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080267879A1 (en) * 2007-04-27 2008-10-30 The General Hospital Corporation Novel Imaging Tracers for Early Detection and Treatment of Amyloid Plaques Caused by Alzheimer's Disease and Related Disorders
US20090123373A1 (en) * 2007-11-05 2009-05-14 Yanming Wang Amyloid-imaging agents
US20110085985A1 (en) * 2008-05-30 2011-04-14 Barrow James C Novel substituted azabenzoxazoles
WO2010051196A1 (en) * 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel substituted azabenzoxazoles
WO2010112093A1 (en) * 2009-04-02 2010-10-07 Biomarin Iga, Ltd. Benzoxazoles for the treatment of duchenne muscular dystrophy

Also Published As

Publication number Publication date
EP4006016A3 (en) 2022-11-16
BR112017004141A2 (pt) 2017-12-12
EP3186233A1 (en) 2017-07-05
EA201790407A1 (ru) 2017-08-31
CN107108534A (zh) 2017-08-29
US20230212190A1 (en) 2023-07-06
IL250803A0 (en) 2017-04-30
EP3186233B1 (en) 2021-08-25
SI3186233T1 (sl) 2022-04-29
AU2015308774A8 (en) 2017-03-23
AU2015308774B2 (en) 2020-03-19
CN116655618A (zh) 2023-08-29
US11059836B2 (en) 2021-07-13
EP4006016A2 (en) 2022-06-01
JP7126541B2 (ja) 2022-08-26
JP6817207B2 (ja) 2021-01-20
ES2898965T3 (es) 2022-03-09
KR102586736B1 (ko) 2023-10-11
AU2015308774A1 (en) 2017-03-16
EP3186233B8 (en) 2021-09-29
BR112017004141B1 (pt) 2022-04-19
CN116655618B (zh) 2025-12-05
EP3186233A4 (en) 2018-05-30
CA2959501A1 (en) 2016-03-03
IL250803B (en) 2021-06-30
WO2016033445A1 (en) 2016-03-03
JP2017528519A (ja) 2017-09-28
DK3186233T3 (da) 2021-11-22
MX380810B (es) 2025-03-12
SG11201701600QA (en) 2017-03-30
HRP20211778T1 (hr) 2022-03-18
BR112017004141B8 (pt) 2022-08-02
KR20170046173A (ko) 2017-04-28
PT3186233T (pt) 2021-12-02
MX2017002703A (es) 2018-01-16
US20170283436A1 (en) 2017-10-05
JP2021059576A (ja) 2021-04-15
US10479802B2 (en) 2019-11-19
PL3186233T3 (pl) 2022-02-28
EA035646B1 (ru) 2020-07-21
HUE056957T2 (hu) 2022-04-28
US20200102328A1 (en) 2020-04-02
MX2021003311A (es) 2021-05-14
KR20220148298A (ko) 2022-11-04
US12258355B2 (en) 2025-03-25
KR102456946B1 (ko) 2022-10-21
CA2959501C (en) 2023-10-10

Similar Documents

Publication Publication Date Title
CN107108534B (zh) 用于成像亨廷顿蛋白的探针
CN107105667B (zh) 用于成像亨廷顿蛋白的探针
CN108135172B (zh) 用于成像亨廷顿蛋白的探针
US12083108B2 (en) Compounds for targeting mutant huntingtin protein and uses thereof
KR102410760B1 (ko) 헌팅틴 단백질을 영상화하기 위한 프로브
EP3190888B1 (en) Probes for imaging huntingtin protein
HK1240583B (en) Probes for imaging huntingtin protein
HK1241223A1 (en) Probes for imaging huntingtin protein
HK1241223B (en) Probes for imaging huntingtin protein

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant